CC
HZNP

Centiva Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Centiva Capital’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,500
Closed -$566K – 2273
2023
Q2 		$566K Buy
5,500
+5,000
+1,000% +$528K 0.01% 771
2023
Q1 		$54.6K Sell
500
-54,500
-99% -$6.02M ﹤0.01% 1376
2022
Q4 		$6.26M Buy
55,000
+54,500
+10,900% +$4.53M 0.18% 113
2022
Q3 		$31K Buy
+500
New +$34.9K ﹤0.01% 1362

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Centiva Capital's HZNP Position: Q4 2023 in Review

Centiva Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 277,625 shares — an estimated $32.1M sold.

Centiva Capital first reported a position in HZNP in Q1 2020 and held it in 9 quarters. The position peaked at $32.1M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Centiva Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Centiva Capital sold 277,625 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $32.1M.
  • Centiva Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 9 quarters.
  • Centiva Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $32.1M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.